WSTAM
DGX icon

Wilbanks Smith & Thomas Asset Management’s Quest Diagnostics DGX Stock Holding History

Wilbanks Smith & Thomas Asset Management’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-607
Closed -$65K – 579
2018
Q3 		$65K Buy
+607
New +$66.6K ﹤0.01% 624

Other funds holding DGX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
FMI
Fiduciary Management Inc Milwaukee, Wisconsin $8.06B AUM 6.78% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Wilbanks Smith & Thomas Asset Management's DGX Position: Q4 2018 in Review

Wilbanks Smith & Thomas Asset Management sold out of Quest Diagnostics (DGX) in Q4 2018, closing a stake of 607 shares — an estimated $65K sold.

Wilbanks Smith & Thomas Asset Management first reported a position in DGX in Q3 2018 and held it in 1 quarter. The position peaked at $65K in Q3 2018. 624 funds tracked by Wall St. Rank hold DGX as of Q4 2018.

  • Wilbanks Smith & Thomas Asset Management reported no remaining Quest Diagnostics position as of Q4 2018 after selling out during the quarter.
  • Wilbanks Smith & Thomas Asset Management sold 607 Quest Diagnostics shares in Q4 2018, an estimated $65K.
  • Wilbanks Smith & Thomas Asset Management first reported a position in Quest Diagnostics in Q3 2018 and held it in 1 quarter.
  • Wilbanks Smith & Thomas Asset Management's Quest Diagnostics position peaked at $65K in Q3 2018.
  • 624 funds tracked by Wall St. Rank held Quest Diagnostics as of Q4 2018.

Based on Wilbanks Smith & Thomas Asset Management's 13F filing for Q4 2018, filed 8 Feb 2019.